Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (41,276)	$ 41,798	$ (85,469)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	14,489	13,132	14,141
Loss (gain) on disposal of property and equipment	110	0	(4,952)
Loss on sale of marketable securities	826	779	0
Unrealized foreign currency exchange gain	(349)	(8,969)	(6,252)
Gains on waiver of research and development grants and other	0	(1,498)	(589)
Remeasurement of related party acquisition-related contingent consideration	49,285	30,957	60,503
Remeasurement of related party financing-related royalty agreements	6,548	4,883	3,319
Change in deferred tax and income tax deferred charge	(4,000)	69	(2,113)
Stock-based compensation expense	14,679	7,741	2,690
Increase (decrease) in cash from:
Accounts receivable	(10,050)	(8,440)	3,249
Inventories	1,831	3,036	(3,112)
Prepaid expenses and other current assets	3,412	(684)	(2,329)
Research and development tax credit receivable	397	2,975	13,210
Accounts payable & other current liabilities	(434)	(8,533)	7,219
Deferred revenue	(2,923)	3,815	(55)
Accrued expenses	6,764	3,376	452
Accrued income taxes	1,778	(393)	70
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(20,252)	0	0
Royalty payments for related party payable in excess of original fair value	(2,469)	0	0
Other long-term assets and liabilities	535	249	(10,599)
Net cash provided by (used in) operating activities	18,901	84,293	(10,617)
Cash flows from investing activities:
Purchases of property and equipment	(1,201)	(1,629)	(1,728)
Proceeds from disposal of property and equipment	0	0	13,242
Acquisitions of businesses, including cash acquired and other adjustments	628	0	0
Proceeds from sales of marketable securities	71,546	48,308	24,993
Purchases of marketable securities	(107,603)	(78,409)	(79,590)
Net cash used in investing activities	(36,630)	(31,730)	(43,083)
Cash flows from financing activities:
Reimbursement of loans	0	(4,911)	(34,186)
Reimbursement of conditional R&D grants	(277)	(747)	(355)
Principal payments on capital lease obligations	0	0	(161)
Earn-out payments for related party contingent consideration	(6,892)	(24,526)	(1,357)
Royalty payments for related party payable	(1,225)	(3,371)	(206)
Excess tax benefit from stock-based compensation	0	2,814	0
Cash proceeds from issuance of ordinary shares and warrants	440	6,990	132,260
Net cash provided by (used in) financing activities	(7,954)	(23,751)	95,995
Effect of exchange rate changes on cash and cash equivalents	(166)	(3,508)	(9,171)
Net increase (decrease) in cash and cash equivalents	(25,849)	25,304	33,124
Cash and cash equivalents at January 1	65,064	39,760	6,636
Cash and cash equivalents at December 31	39,215	65,064	39,760
Supplemental disclosures of cash flow information:
Income tax paid	27,180	42,121	403
Interest paid	$ 788	$ 4,738	$ 4,431